Follow
Dung Le
Dung Le
Verified email at jhmi.edu
Title
Cited by
Cited by
Year
PD-1 blockade in tumors with mismatch-repair deficiency
DT Le, JN Uram, H Wang, BR Bartlett, H Kemberling, AD Eyring, ...
New England Journal of Medicine 372 (26), 2509-2520, 2015
73532015
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
DT Le, JN Durham, KN Smith, H Wang, BR Bartlett, LK Aulakh, S Lu, ...
Science 357 (6349), 409-413, 2017
42302017
Detection of circulating tumor DNA in early-and late-stage human malignancies
C Bettegowda, M Sausen, RJ Leary, I Kinde, Y Wang, N Agrawal, ...
Science translational medicine 6 (224), 224ra24-224ra24, 2014
36602014
Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial
SJ Antonia, JA López-Martin, J Bendell, PA Ott, M Taylor, JP Eder, ...
The Lancet Oncology 17 (7), 883-895, 2016
10652016
Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair–deficient cancer: Results from the phase II KEYNOTE-158 study
A Marabelle, DT Le, PA Ascierto, AM Di Giacomo, A De Jesus-Acosta, ...
Journal of Clinical Oncology 38 (1), 1, 2020
10342020
Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial
K Muro, HC Chung, V Shankaran, R Geva, D Catenacci, S Gupta, JP Eder, ...
The lancet oncology 17 (6), 717-726, 2016
9052016
Primary Resistance to PD-1 Blockade Mediated by JAK1/2 MutationsPrimary Resistance to PD-1 Blockade
DS Shin, JM Zaretsky, H Escuin-Ordinas, A Garcia-Diaz, S Hu-Lieskovan, ...
Cancer discovery 7 (2), 188-201, 2017
8472017
Pembrolizumab in microsatellite-instability–high advanced colorectal cancer
T André, KK Shiu, TW Kim, BV Jensen, LH Jensen, C Punt, D Smith, ...
New England Journal of Medicine 383 (23), 2207-2218, 2020
6882020
Microsatellite instability as a biomarker for PD-1 blockade
JC Dudley, MT Lin, DT Le, JR Eshleman
Clinical Cancer Research 22 (4), 813-820, 2016
6192016
Evolutionary dynamics of cancer in response to targeted combination therapy
I Bozic, JG Reiter, B Allen, T Antal, K Chatterjee, P Shah, YS Moon, ...
elife 2, e00747, 2013
5832013
Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial
P Sharma, MK Callahan, P Bono, J Kim, P Spiliopoulou, E Calvo, ...
The lancet oncology 17 (11), 1590-1598, 2016
5792016
Safety and survival with GVAX pancreas prime and Listeria monocytogenes–expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer
DT Le, A Wang-Gillam, V Picozzi, TF Greten, T Crocenzi, G Springett, ...
Journal of clinical oncology 33 (12), 1325, 2015
5402015
Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer
DT Le, E Lutz, JN Uram, EA Sugar, B Onners, S Solt, L Zheng, LA Diaz Jr, ...
Journal of immunotherapy (Hagerstown, Md.: 1997) 36 (7), 382, 2013
5172013
Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors
FB Cortazar, KA Marrone, ML Troxell, KM Ralto, MP Hoenig, JR Brahmer, ...
Kidney international 90 (3), 638-647, 2016
4372016
A lethally irradiated allogeneic granulocyte-macrophage colony stimulating factor-secreting tumor vaccine for pancreatic adenocarcinoma: a phase II trial of safety, efficacy …
E Lutz, CJ Yeo, KD Lillemoe, B Biedrzycki, B Kobrin, J Herman, E Sugar, ...
Annals of surgery 253 (2), 328, 2011
4012011
Phase II open-label study of pembrolizumab in treatment-refractory, microsatellite instability–high/mismatch repair–deficient metastatic colorectal cancer: KEYNOTE-164
DT Le, TW Kim, E Van Cutsem, R Geva, D Jäger, H Hara, M Burge, ...
Journal of Clinical Oncology 38 (1), 11, 2020
3952020
CheckMate-032 study: efficacy and safety of nivolumab and nivolumab plus ipilimumab in patients with metastatic esophagogastric cancer
YY Janjigian, J Bendell, E Calvo, JW Kim, PA Ascierto, P Sharma, PA Ott, ...
Journal of Clinical Oncology 36 (28), 2836, 2018
3822018
Subchronic phencyclidine administration reduces mesoprefrontal dopamine utilization and impairs prefrontal cortical-dependent cognition in the rat
JD Jentsch, A Tran, D Le, KD Youngren, RH Roth
Neuropsychopharmacology 17 (2), 92-99, 1997
3661997
A Live-Attenuated Listeria Vaccine (ANZ-100) and a Live-Attenuated Listeria Vaccine Expressing Mesothelin (CRS-207) for Advanced Cancers: Phase I Studies of Safety and Immune …
DT Le, DG Brockstedt, R Nir-Paz, J Hampl, S Mathur, J Nemunaitis, ...
Clinical cancer research 18 (3), 858-868, 2012
3442012
Allogeneic granulocyte macrophage colony-stimulating factor–secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: a pilot …
D Laheru, E Lutz, J Burke, B Biedrzycki, S Solt, B Onners, I Tartakovsky, ...
Clinical Cancer Research 14 (5), 1455-1463, 2008
3332008
The system can't perform the operation now. Try again later.
Articles 1–20